Corbus Pharmaceuticals

Corbus Pharmaceuticals is a biotechnology company engaged in the research and development of novel therapeutics to address serious illnesses. Their current focus includes innovative studies in Nectin-4, Integrin Biology, and CB1R Inverse Agonist Biology. They are actively progressing in their clinical pipeline with treatments like CRB-601 for advanced solid tumors and CRB-701 for metastatic cervical cancer, which has received FDA Fast Track Designation. Corbus Pharmaceuticals aims to connect innovation with purpose, pushing the boundaries of medicinal research and offering new hope for challenging health conditions. The company is publicly traded on Nasdaq under the ticker CRBP.